Skip to content
Menu

Profound Medical Corp. PROF

Full chart Compare
Set alert

Price alert · PROF

All alert types
6.59 USD -0.32 (-4.63%)

Regular-session close

6.59 0.00 0.00%

After hours · Nov 19, 4:39 PM ET

6.59 Day range 6.98
4.80 52-week range 8.95
YTD
-16.26%
1 year
+8.57%

 

No chart data for this range yet.
Market cap
241.37M
Revenue (ttm)
8.98M
EPS (ttm)
-0.94
Shares out
30.03M
Forward P/E
-7.95
YTD return
-16.26%
1-year return
+8.57%
50-day average
7.73
200-day average
8.29
Volume
103.85K
Avg volume
206.68K
Open
6.97
Previous close
6.91
Day's range
6.59 – 6.98
52-week range
4.80 – 8.95
Beta
0.83
Analysts
Strong Buy
Price target
15.30 (+132.2%)

Key statistics

Enterprise value
157.76M
Price / sales
23.40
Price / book
5.55
Revenue growth
63.90%
Free cash flow
-14.79M
Total cash
27.12M
Total debt
6.23M
Return on equity
-90.17%

Fundamental scorecard

8 of 25 checks passed on PROF’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PROF Revenue — quarterly 9.83M
PROF Net income — quarterly -7.72M
PROF EPS — quarterly -0.21

Earnings

PROF recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.33-0.38-0.05-15.15%
Aug 8, 2024Jun 1, 2024-0.28-0.280.000.00%
Aug 8, 2024Jun 1, 2024-0.28———
May 9, 2024Mar 1, 2024-0.31———
May 9, 2024Mar 1, 2024-0.31-0.26+0.05+16.13%
Mar 7, 2024Dec 1, 2023-0.28-0.42-0.14-50.00%

Upgrades / downgrades

PROF analyst upgrades and downgrades
DateFirmActionFromTo
Jul 16, 2024StifelupHoldBuy
Mar 11, 2024Alliance Global PartnersmainBuyBuy
Mar 8, 2024StifelmainHoldHold
Jan 4, 2024Alliance Global PartnersmainBuyBuy
Nov 28, 2023Stifelinit—Hold
Aug 4, 2023Raymond JamesdownStrong BuyOutperform

About Profound Medical Corp.

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Sector
Healthcare
Industry
Medical Devices
Country
Canada

News

Your note

Sign in to keep a note on PROF — it syncs with the Stock Master app.

Institution ownership

PROF institution ownership
Holder% heldSharesValueReported
FIL LTD5.11%1,535,00010.74MSep 29, 2024
Gagnon Securities, LLC4.89%1,467,24710.27MSep 29, 2024
Letko, Brosseau & Associates Inc.3.99%1,198,7758.39MSep 29, 2024
Raymond James Financial Services Advisors, Inc.2.53%760,4575.32MSep 29, 2024
Timelo Investment Management Inc.2.50%751,8075.26MSep 29, 2024
Gagnon Advisors, LLC2.49%747,2265.23MSep 29, 2024

Fund ownership

PROF fund ownership
Holder% heldSharesValueReported
Royce Micro-Cap Fund0.76%227,9371.60MSep 29, 2024
Royce Micro Cap Trust0.63%189,1001.32MSep 29, 2024
Royce Capital Fund-Micro-Cap Portfolio0.33%100,163701.14KSep 29, 2024
Royce Small-Cap Fund0.17%52,098364.69KSep 29, 2024
Fidelity NASDAQ Composite Index Fund0.05%14,04998.34KOct 30, 2024
Dimensional ETF Tr-Dimensional International Small Cap ETF0.00%1,1888.32KJul 30, 2024